Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients

Annals of Hematology

Volumn 90, Issue 12, 2011, Pages 1457-1465

  Schlenke, Peter ^a,b   Hagenah, Wibke ^b   Irsch, Johannes ^c   Sundin, David ^d   Corash, Laurence ^d,e   Lin, Lily ^d   Kirchner, Holger ^b   Wagner, Thomas ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Cerus Europe BV   (Netherlands)

^d CERUS CORPORATION   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amotosalen; Pathogen inactivation; Platelets; Thrombocytopenia

Indexed keywords

AMOTOSALEN; THROMBOCYTE CONCENTRATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CAUSE OF DEATH; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EYE EDEMA; FEMALE; FEVER; HEMATOLOGIC DISEASE; HEMOSTASIS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PRURITUS; RASH; SEPSIS; SHOCK; STEM CELL TRANSPLANTATION; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; URTICARIA; VASCULAR DISEASE; WEAKNESS;

EID: 85027958503     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1222-3     Document Type: Article

References (26)

1. WG Murphy M Foley C Doherty G Tierney A Kinsella A Salami E Cadden P Coakley 2008 Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety Vox Sang 95 13 19 18393945 10.1111/j.1423-0410.2008. 01051.x 1:STN:280:DC%2BD1M%2Fns1GmsQ%3D%3D (Pubitemid 351799415)
2. H Schrezenmeier G Walther-Wenke T Müller F Weinauer A Younis T Holland-Letz G Geis J Asmus U Bauerfeind J Burkhart R Deitenbeck E Förstemann W Gebauer B Höchsmann A Karakassopoulos U-M Liebscher W Sänger M Schmidt F Schunter W Sireis E Seifried 2007 Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets Transfusion 47 644 652 17381623 10.1111/j.1537-2995.2007.01166.x (Pubitemid 46449625)
3. RY Dodd EP Notari SL Stramer 2002 Current prevalence and incidence of infectious disease markers and estimated window period risk in the American Red Cross blood donor population Transfusion 42 975 979 12385406 10.1046/j.1537-2995.2002.00174.x 1:STN:280:DC%2BD38nislKqsw%3D%3D
4. RY Dodd D Leiby 2004 Emerging infectious threats to the blood supply Annu Rev Med 55 191 207 14746517 10.1146/annurev.med.55.091902.103831 1:CAS:528:DC%2BD2cXitVWrtbk%3D (Pubitemid 38316723)
5. JP Allain C Bianco MA Blajchman ME Brecher M Busch D Leiby L Lin S Stramer 2005 Protecting the blood supply from emerging pathogens: the role of pathogen inactivation Transfus Med Rev 19 2 110 126 15852240 10.1016/j.tmrv.2004.11.005 (Pubitemid 40544291)
6. L Corash L Lin 2004 Novel processes for inactivation of leukocytes to prevent transfusion-associated graft versus host disease Bone Marrow Transplant 33 1 7 14647263 10.1038/sj.bmt.1704284 1:STN:280:DC%2BD2c%2FgslWjtw%3D%3D (Pubitemid 38159696)
7. P Schlenke 2004 Protection against transfusion-associated graft versus host disease in blood transfusion: is gamma-irradiation the only answer? Transfus Med Hemother 31 suppl 1 24 31 10.1159/000076977 (Pubitemid 38250522)
8. L Lin R Dikeman B Molini, et al. 2004 Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria Transfusion 44 1496 1504 15383024 10.1111/j.1537-2995.2004.04125.x 1:CAS:528:DC%2BD2cXptlKlsLg%3D (Pubitemid 39318986)
9. L Lin CV Hanson HJ Alter, et al. 2005 Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light Transfusion 45 580 590 15819680 10.1111/j.0041-1132.2005. 04316.x 1:CAS:528:DC%2BD2MXjvVGgtrs%3D
10. WC Van Voorhis LK Barrett RT Eastman R Alfonso K Dupuis 2003 Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV Antimicrob Agents Chemother 47 475 479 12543646 10.1128/AAC.47.2.475-479.2003 (Pubitemid 36158069)
11. RT Eastman LK Barrett K Dupuis FS Buckner WC Van Voorhis 2005 Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation Transfusion 45 1459 1463 16131378 10.1111/j.1537-2995.2005.00552.x 1:CAS:528:DC%2BD2MXhtVOrtrbL (Pubitemid 44194649)
12. JA Grass DJ Hei K Metchette GD Cimino GP Wiesehahn L Corash L Lin 1998 Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA Blood 91 2180 2188 9490707 1:CAS:528:DyaK1cXhvVGjsrs%3D (Pubitemid 28185525)
13. JA Grass T Wafa A Reames D Wages L Corash JLM Ferrera L Lin 1999 Prevention of transfusion-associated graft-versus host disease by photochemical treatment Blood 93 3140 3147 10216113 1:CAS:528:DyaK1MXivVylurs%3D (Pubitemid 29200809)
14. DJ Hei JA Grass L Lin L Corash G Cimino 1999 Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light Transfusion 39 239 248 10204585 10.1046/j.1537-2995.1999.39399219279.x 1:CAS:528:DyaK1MXit1WntL8%3D (Pubitemid 29144907)
15. D van Rhenen H Gulliksson J-P Cazenave D Pamphilon P Ljungman H Klueter H Vermeij M Kappers-Klune G de Greef M Laforet B Lioure K Davis S Marblie V Mayaudon J Flament J Conlan M Conlan L Lin P Metzel D Buchholz L Corash 2003 Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial Blood 101 2426 2433 12456508 10.1182/blood-2002-03-0932 (Pubitemid 36302092)
16. J McCullough D Vesole R Benjamin S Slichter A Pineda E Snyder E Stadtmauer I Lopez-Plaza S Coutre RG Strauss LT Goodnough JL Fridey T Raife R Cable S Murphy IVF Howard K Davis JS Lin P Metzel L Corash A Koutsoukos L Lin D Buchholz M Conlan 2004 Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial Blood 104 1534 1541 15138160 10.1182/blood-2003-12-4443 1:CAS:528:DC%2BD2cXnt1ersL8%3D (Pubitemid 39166535)
17. J-P Cazenave C Waller I Mendel D Kientz G Kandel J-P Raidot ML Wiesel M Laforet H Isola 2008 Clinical experience with conventional versus INTERCEPT platelet concentrates transfused to all patients during two one-year periods: reduction of adverse events with equivalent use of blood products Vox Sang 95 suppl 1 305 306
18. J-C Osselaer N Messe T Hervig J Bueno E Castro A Espinosa P Accorsi K Junge M Jacques J Flament L Corash 2008 A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment Transfusion 48 1061 1071 18346019 10.1111/j.1537-2995.2008.01643.x (Pubitemid 351793479)
19. J-C Osselaer J-P Cazenave M Lambermont O Garraud M Hidajat L Barbolla R Tardivel L Defoin C Waller I Mendel JP Raidot G Kandel R De Meuter P Fabrigli D Dehenau JL Arroyo F Padron H Gouezec M Corral M Jacquet D Sundin L Lin L Corrash 2008 An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment Vox Sang 94 315 323 18248574 10.1111/j.1423-0410.2007.01035.x 1:STN:280: DC%2BD1c3lsFWlsw%3D%3D (Pubitemid 351535733)
20. L Lin M Conlan J Tessman G Cimino S Porter 2005 Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment Transfusion 45 1610 1620 16181212 10.1111/j.1537-2995. 2005.00554.x
21. S Slichter K Davis H Enright H Braine T Gemsheimer K-J Kao T Kickler E Lee J McFarland J McCullough G Rodey CA Schiffer R Woodson 2005 Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients Blood 105 4106 4114 15692069 10.1182/blood-2003-08-2724 1:CAS:528:DC%2BD2MXktlSrt7s%3D (Pubitemid 40656162)
22. HG Klein D Anderson MJ Bernardi R Cable W Carey JS Hoch N Robitaille MLA Sivilotti F Smaill 2007 Pathogen inactivation: making decisions about new technologies Transfusion 47 2338 2347 18036075 10.1111/j.1537-2995.2007.01512.x (Pubitemid 350151213)
23. JF Bishop JP Matthews, et al. 1991 Factors influencing 20-hour increments after platelet transfusion Transfusion 31 392 396 2048176 10.1046/j.1537-2995. 1991.31591263191.x 1:STN:280:DyaK3M3mtlWqsw%3D%3D
24. A Ishida M Handa, et al. 1998 Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation-a prospective analysis Transfusion 38 839 847 9738624 10.1046/j.1537-2995.1998.38998409004.x 1:STN:280:DyaK1cvgvFSjtg%3D%3D (Pubitemid 28421645)
25. SJ Slichter RM Kaufman SF Assmann, et al. 2008 Effects of prophylactic platelet (plt) dose on transfusion (tx) outcomes (PLADO Trial) Blood 112 no.11 111
26. 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCL(S-59) and ultraviolet A light Transfusion 44 1732 1740 15584988 10.1111/j.0041-1132.2004.04145.x (Pubitemid 39644058)